Cancerappy: Using AI to Advance Cancer Research

Cancerappy: Using AI to Advance Cancer Research

Since 2019, Cancerappy has been harnessing the power of artificial intelligence to transform cancer research, from improving detection and diagnosis to developing more effective treatments with fewer side effects. We’re putting AI to work in areas like genomics, protein structure prediction, and drug discovery.

Here’s how AI drives our programs:

  • New Drug Development: AI speeds up drug discovery, making it faster, more cost-effective, and precise. It helps us screen drugs, predict multi-target effects, and find new uses for existing drugs.

  • Identifying Targets: AI enables us to design proteins and identify new therapeutic targets, opening doors to innovative treatments.

  • Handling Big Data: Cancer research generates huge data sets. AI helps us spot patterns, clean up data, and draw accurate conclusions.

  • Linking Data for Deeper Insights: By connecting data from diverse technologies, AI gives us a richer perspective and opens new research pathways.

At Cancerappy, AI is more than a tool—it’s a game-changer in our mission to make cancer treatments more effective and targeted.

Cancerappy at #Bventure24

Cancerappy at #Bventure24

We’re back at Bventure! Cancerappy is actively participating in this innovation event through the University of Deusto, joining the roundtable discussion, “The Value of Talent in an AI Startup.” On Tuesday, Oct 15th, our CEO will share insights on how AI is impacting our work and driving progress in our field. Don’t miss it!

China health innovation ecosystem

China health innovation ecosystem

A Cancerappy delegation has participated in a roadshow of European companies to learn about the innovative health ecosystem in the Shanghai and Wuxi area.

Our CEO has had the opportunity to hold various meetings with different agents of the innovation ecosystem, especially in the health sector, including investors, local government officials, leaders of research and innovation centers, as well as biotech companies and laboratories.

We have been able to observe first-hand how China has evolved to reach a peak of technological innovation in the health sector that is enviable and leading in the world.

From all these meetings, we have achieved several collaboration agreements that represent the beginning of a great business adventure that Cancerappy is going to begin imminently.

CancerAppy Contributes to Innovative Scientific Paper on ADCs in Clinical Use

CancerAppy Contributes to Innovative Scientific Paper on ADCs in Clinical Use

biospain_cancerappy

CancerAppy pioneers in ADC research, contributing to a transformative scientific paper. Our team’s dedication unveils insights on payload properties, shaping the future of ADC therapies. A crucial leap in cancer treatment. 

We are proud to announce our significant contribution to a seminal scientific paper focused on Antibody-Drug Conjugates (ADCs) in the clinical landscape. The paper delves, among other aspects, into an extensive analysis of the physicochemical properties of ADC payloads, yielding crucial insights pivotal for the strategic design and advancement of ADC therapies.

As a leader in innovative biotechnological solutions, CancerAppy team played a high relevant role in the collaborative effort that culminated in this comprehensive examination. The paper’s findings promise to revolutionize the development and optimization of ADCs, offering a clearer understanding of the relationship between payload properties and therapeutic efficacy.

ADCs represent a pivotal therapeutic advancement, effectively applied across diverse clinical scenarios. Comprising antibodies targeting tumor-associated antigens (TAAs), cytotoxic payloads, and binding linkers, ADCs have primarily focused research on target identification, antibody design, and linker optimization, leaving other critical clinical facets understudied. In this work, the researches performed a comprehensive assessment of approved ADCs and analyzed properties such as payload physicochemical attributes, potency, drug antibody ratio (DAR), exposure–response correlations, and development strategies. Optimal clinical candidates feature ideal payload properties and cleavable linkers, particularly impactful in low TAA expression contexts. Additionally, early clinical tactics, including altered dosing schedules, aim for enhanced efficiency. This analysis emphasizes overlooked facets essential for ADC cancer development, proposing avenues for refinement.

Dr. Elisa Poyatos, Chief Scientific Officer at CancerAppy, expressed enthusiasm about the company’s involvement in this groundbreaking endeavor, stating, “Our team’s commitment to pushing the boundaries of scientific knowledge has motivated our dive into the intricate details of ADCs. By conducting thorough analysis and partnering with respected researchers, we’ve uncovered crucial understandings about the physicochemical characteristics of ADC payloads. This knowledge might empower the industry to create therapies that are more effective and impactful.”

This collaborative scientific effort underscores CancerAppy’s commitment to pioneering advancements in biotechnology and reinforces its dedication to fostering innovation within the industry.

The complete work has been published in the Journal of Hematology & Oncology, with an impact factor of 28.5 (2022); and can be read with open access at the following link: https://jhoonline.biomedcentral.com/articles/10.1186/s13045-023-01519-0

For media inquiries, please contact info@cancerappy.com

CancerAppy at ESMO Congress: Pioneering Research Unveiled!

CancerAppy at ESMO Congress: Pioneering Research Unveiled!

biospain_cancerappy

CancerAppy’s groundbreaking study at ESMO Congress (Oct ’23) reveals profound insights into Treg impact on tumor immune responses. Unearthing common transcripts and potential predictors, our AI-driven research shapes the future of cancer treatment.

CancerAppy has contributed to a groundbreaking study unveiled at the esteemed ESMO Congress in Madrid (October 2023) Our pioneering biotech, harnessing the power of AI in Drug Design, has taken a major step in understanding immune cell populations within tumor environments, specifically the regulatory CD4+ T cells (Tregs), and their profound impact on tumor immune responses.

Intriguing insights emerged from the analysis of breast cancer datasets, unveiling a mere 0.5% of the transcriptome intricately linked to Treg presence. Notably, we unearthed four common transcripts shared across various cancer subtypes (BIRC6, MAP3K2, USP4, SMG1). Additionally, our study highlighted ten upregulated genes, predominantly expressed at cell membranes, intricately correlated with PDL1/PD1 expression or the presence of macrophages in basal-like/HER2+ tumors.

Several genes—MSR1, CD80, OLR1, ABCA1, TMEM245, ATP13A3—emerged as potential predictors of favorable outcomes and responses to anti-PD(L)1/CTLA4 therapies, illuminating promising avenues to fortify anti-tumor immune activity.

This research highlights the immense potential of modulating Treg responses, offering a compelling glimpse into the future of cancer treatment. Furthermore, it highlights the usefulness of in-depth treatment of existing and available data for decision-making in the design of new drugs and treatments.

Stay tuned as we continue to validate and unlock the transformative impact of these findings. #ESMO2023 #AIDrugDiscovery #CancerResearch #Immunotherapy

BIO Spain

BIO Spain

biospain_cancerappy

We’re excited to be part of BioSpain 2023, and despite our packed schedule, we welcome you to connect with us at the BasqueHealthCluster booth. Explore our groundbreaking work in the world of biotechnology and cancer research. See you there!.

More about BIO Spain